文献速递认知障碍与痴呆

专科记忆门诊中Lecanemab治疗的实施与安全性

Lecanemab Treatment in a Specialty Memory Clinic.
PubMed 文献 · JAMA Neurol · 2025-01-01

该回顾性分析纳入华盛顿大学记忆诊断中心2023年8月至2024年10月启动Lecanemab治疗的234例早期症状性AD患者,评估输注反应、ARIA及停药情况。平均治疗6.5个月期间,22%发生ARIA,5.7%出现症状性ARIA,无大出血或死亡;轻度痴呆患者症状性ARIA发生率为27%,而MCI或极轻度痴呆为1.8%。

要点

  • 234例早期症状性AD患者接受Lecanemab 10 mg/kg 每2周静脉输注,平均治疗6.5个月。
  • 输注反应发生87例(37%),通常轻微;22%发生ARIA,5.7%为症状性ARIA。
  • 轻度痴呆患者症状性ARIA发生率为27%,MCI或极轻度痴呆为1.8%。

核心结论

  • 单个专科记忆门诊在14个月内为234例患者启动Lecanemab治疗,包括ARIA在内的显著不良事件频率可控。

研究设计与样本

  • 回顾性分析 consecutive 患者,纳入2023年8月1日至2024年10月1日在华盛顿大学记忆诊断中心(门诊专科记忆门诊)启动Lecanemab治疗的234例早期症状性AD患者。

主要发现

  • 234例患者平均年龄74.4岁(SD 6.7),女性117例(50%),男性117例(50%)。
  • 输注相关反应发生于87例(37%),通常轻微。
  • 194例研究期间有ARIA风险的患者中,44例(23%)在启动Lecanemab前有至少1处微出血和/或 superficial siderosis。
  • 平均治疗6.5个月期间,42例(22%)发生ARIA;29例(15%)发生ARIA-E伴或不伴ARIA-H,13例(6.7%)发生孤立性ARIA-H。
  • 11例(5.7%)发生症状性ARIA,其中2例(1.0%)有临床严重症状;无患者发生大出血或死亡。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Two monoclonal antibodies targeting amyloid plaques, lecanemab and donanemab, have received traditional US Food and Drug Administration (FDA) approval for the treatment of early symptomatic Alzheimer disease (AD). The most significant adverse events associated with these therapies are infusion-related reactions and amyloid-related imaging abnormalities (ARIA) with edema/effusion (ARIA-E) and/or hemorrhage/hemosiderin deposition (ARIA-H). The feasibility and safety of providing these treatments in clinical practice is unclear. OBJECTIVE: To examine the feasibility and safety of treating patients in specialty memory clinics with lecanemab. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis of consecutive patients in whom lecanemab was initiated between August 1, 2023, and October 1, 2024, at Washington University Memory Diagnostic Center, an outpatient specialty memory clinic. Lecanemab was initiated in 234 patients with early symptomatic AD. Eligibility was based on the FDA label and appropriate use recommendations with occasional exceptions. EXPOSURE: Patients were treated with lecanemab, 10 mg/kg, intravenously every 2 weeks. MAIN OUTCOMES AND MEASURES: Infusion-related reactions, ARIA, and withdrawal from treatment were assessed. RESULTS: The 234 patients treated with lecanemab had a mean age of 74.4 (SD, 6.7) years, 117 were female (50%), and 117 were male (50%). Infusion-related reactions occurred in 87 patients (37%) and were typically mild. Of the 194 patients at risk for ARIA during the study period, 44 had at least 1 microhemorrhage and/or superficial siderosis before initiation of lecanemab (23%). Over an average treatment period of 6.5 months, 42 total patients (22%) developed ARIA; 29 developed ARIA-E with or without ARIA-H (15%) and 13 developed isolated ARIA-H (6.7%). Eleven patients (5.7%) developed symptomatic ARIA, 2 of those patients (1.0%) with clinically severe symptoms. No patients developed a macrohemorrhage or died. Patients with mild dementia had a 27% rate of symptomatic ARIA; those with mild cognitive impairment or very mild dementia had a 1.8% rate. Overall, 23 of 234 patients (9.8%) withdrew from treatment for various reasons, 10 for ARIA (4.3%). CONCLUSIONS AND RELEVANCE: A single-specialty memory clinic initiated lecanemab treatment in 234 patients over 14 months. The frequency of significant adverse events, including ARIA, was manageable. These results may inform discussions about the risks of anti-amyloid treatments.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Paczynski M, Hofmann A, Posey Z, et al. Lecanemab Treatment in a Specialty Memory Clinic. JAMA Neurol. 2025. PMID: 40354064. doi:10.1001/jamaneurol.2025.1232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。